Join the Topix community today: 

Sign Up

 | 

Sign In

Become a Topix Editor today!

topix
Advertisment

Forum & Polls

News

NewsWire

RSS icon mobile icon Add headlines icon

Angioedema News

News on Angioedema continually updated from thousands of sources around the net.

Thursday Apr 24 | BioSpace

More...

“Cubist brings a wealth of clinical resources and commercial expertise in the development of a hospital-based therapy, which will serve to maximize the potential of DX-88 in the prevention of blood loss during surgery”

CAMBRIDGE, Mass. & LEXINGTON, Mass.-- --Dyax Corp. and Cubist Pharmaceuticals, Inc. via BioSpace

Comment?

Related Topix: Cambridge, MA, Lexington, MA, Biotech, Cubist Pharmaceuticals, Healthcare Industry, Health, Dyax

Mar 18, 2008 | Med Ad News

Lev Presents Results of Phase III Study Supporting Safety and...

“Patients with hereditary angioedema live with the constant threat of severe and potentially life-threatening angioedema attacks”

Lev Presents Results of Phase III Study Supporting Safety and Efficacy of Cinryze as Prophylactic Therapy for HAE PHILADELPHIA & NEW YORK-- --Mar 18, 2008 - Lev Pharmaceuticals, Inc. via Med Ad News

Comment?

Related Topix: Immunology, Biology, Science, Medicine, Health

Feb 14, 2008 | BioWorld

Dyax Signs Sanofi to Antibody Deal Potentially Worth $500M

“It's a very promising drug that we've had excellent results with”

While it awaits results from a confirmatory trial with hereditary angioedema drug DX-88, Cambridge, Mass.-based Dyax Corp. via BioWorld

Comment?

Related Topix: Biotech, SanofiSynthlabo, Medicine, Health, Healthcare Law, Law

Dec 21, 2007 | Reuters UK

FDA gives Jerini angioedema drug priority review

German biotech firm Jerini AG said on Friday that U.S. regulators at the Food and Drug Administration have granted priority review of its Icatibant drug for the treatment of skin-swelling disease hereditary ... via Reuters UK

Comment?

Related Topix: Medicine, Health, Food and Drug Administration

Dec 19, 2007 | BioWorld

Pharming Shares Sink On CHMP Rebuff For Rhucin

“It feels like the same issue right now”

Shares in Pharming Group NV sank by more than 65 percent on news that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on a marketing authorization ... via BioWorld

Comment?

Related Topix: Marketing, Medicine, Health

Nov 13, 2007 | Newswise

Novel Therapies May At Last Bring Relief for U.S. Hereditary Angioedema Patients

“The rarity of the diagnosis means that even the most specific of tests may be wrong”

Although there is currently no treatment approved by the Federal Drug Administration for acute attacks of hereditary angioedema - ' a genetic disease causing swelling of extremities, face and internal organs ... via Newswise

Comment?

Related Topix: Medicine, Health, Food and Drug Administration, Pain

Oct 25, 2007 | Canadian Business Magazine

Dyax's Loss Widens As Costs Rise to Develop Rare Blood Disease Treatment, Revenue Declines

Drug developer Dyax Corp. said Wednesday its third-quarter loss widened on higher costs for its DX-88 hereditary angioedema treatment candidate and lower revenue. via Canadian Business Magazine

Comment?

Related Topix: Medicine, Health, Biotech, Dyax, Healthcare Industry

Angioedema Editors

RoboBlogger

I edit this news page on Topix when no humans are available to help.

Become an editor for today!

Edits History

More Angioedema News

Angioedema News Archives buttonFind the stories you missed in the Archives.

Angioedema News Forum buttonJoin the lively discussion in our Forums.

Angioedema News Wire buttonBrowse continually updated news from the Wire.